Elucid Raises $55M for Cardiac Imaging AI
Elucid raised $55M to expand AI-driven cardiovascular imaging and CT-based diagnostic tools.
AI healthtech is strongest when it targets a specific clinical workflow instead of promising to replace the doctor.
What happened
Boston-based Elucid raised a $55M Series D to expand its AI-driven cardiovascular imaging portfolio. The financing brings total funding to roughly $185M and supports commercial expansion and product development around CT-based cardiovascular diagnostics.
Elucid focuses on using imaging data to help clinicians identify and understand cardiovascular disease risk more precisely.
Why it matters
Cardiovascular disease remains one of the largest and costliest health burdens. Better imaging interpretation can help physicians make earlier and more informed treatment decisions, especially when software can extract signals that are difficult to assess manually.
The value is practical: better workflow support, more consistent analysis and clearer risk assessment inside an existing clinical process.
The bigger picture
AI in healthcare is moving toward focused diagnostic and workflow products. The winners are unlikely to be vague general-purpose “AI doctors.” They are more likely to be companies that solve narrow, high-value clinical problems and can prove performance, reimbursement value and physician trust over time.